Blueprint Medicines Corporation's (BPMC) CEO Jeff Albers on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha]
Blueprint Medicines Corporation (BPMC)
Last blueprint medicines corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
blueprintmedicines.com
Company Research
Source: Seeking Alpha
Blueprint Medicines Corporation (NASDAQ: BPMC Company Participants Kristin Hodous - Senior Manager, Investor Relations Jeff Albers - Chief Executive Officer Dr. Andy Boral - Chief Medical Officer Christy Rossi - Chief Commercial Officer Mike Landsittel - Chief Financial Officer Conference Call Participants Salveen Richter - Goldman Sachs Dane Leone - Raymond James Joe Thome - Cowen and Company Michael Schmidt - Guggenheim Security Eun Yang - Jefferies Andrew Berens - SVB Leerink Reni Benjamin - JMP Securities Arlinda Lee - Canaccord George Farmer - BMO Capital Chris Raymond - Piper Sandler Operator Ladies and gentlemen, thank you for standing by. And welcome to the fourth quarter 2019 Blueprint Medicines Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] And I would now like to hand the conference over to your speaker today, Kristin Hodous. Thank you, and ple
Show less
Read more
Impact Snapshot
Event Time:
BPMC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BPMC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BPMC alerts
High impacting Blueprint Medicines Corporation news events
Weekly update
A roundup of the hottest topics
BPMC
News
- Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update [Yahoo! Finance]Yahoo! Finance
- Blueprint Medicines Co. (NASDAQ: BPMC) was upgraded by analysts at Leerink Partnrs from an "underperform" rating to a "market perform" rating.MarketBeat
- Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR Newswire
- Blueprint Medicines Co. (NASDAQ: BPMC) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $121.00 to $168.00. They now have a "buy" rating on the stock.MarketBeat
- Blueprint Medicines Co. (NASDAQ: BPMC) was upgraded by analysts at SVB Leerink LLC from an "underperform" rating to a "market perform" rating. They now have a $97.00 price target on the stock, up previously from $50.00.MarketBeat
BPMC
Earnings
- 5/2/24 - Beat
BPMC
Sec Filings
- 5/10/24 - Form 4
- 5/6/24 - Form 4
- 5/6/24 - Form 4
- BPMC's page on the SEC website